

August 28, 2018

NEMUS Bioscience to Present at the Rodman & Renshaw 20th Annual Global Investment Conference

Long Beach, Calif., Aug. 28, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- [NEMUS Bioscience, Inc.](http://www.nemusbioscience.com) (OTCQB: NMUS), focused on the development of cannabinoid-based therapeutics to address global medical indications, especially those of unmet medical need, announced today that Dr. Brian Murphy, CEO and Chief Medical Officer, will present at the Rodman & Renshaw 20th Annual Global Investment Conference taking place at the St. Regis Hotel in New York, NY.

PRESENTATION DETAILS:

Date: Thursday – September 6, 2018

Time: 3:25 PM Eastern Time

To view the live webcast, please access the following link at the time of the presentation: <http://www.wsj.com/webcast/rshq28/nmus/>. An archived version of the webcast will be available for 90 days in the investor section of the Nemus Bioscience website.

FORWARD LOOKING STATEMENTS

This press release contains forward-looking statements, including statements about product development, business strategy and milestones, and the studies relating to and the potential benefits of Nemus' proprietary, cannabinoid-based therapeutics. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management's current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition and stock price could be materially negatively affected. In some cases, forward-looking statements can be identified by terminology including "goal," "focus," "aims," "expects," "plans," "believes," "can," "could," "challenge," "predictable," "will," or the negative of these terms or other comparable terminology. We operate in a rapidly changing environment and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make. Risks and uncertainties that may cause actual results to differ materially include, among others, our capital resources, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Risk Factors section of Nemus' most recent annual or quarterly report filed with the Securities and Exchange Commission. Except as expressly required by law, Nemus disclaims any intent or obligation to update these forward-looking statements.

Nemus investors and others should note that we announce material information to the public about the Company through a variety of means, including our website (<http://www.nemusbioscience.com/>), our investor relations website (<http://www.nemusbioscience.com/investor-relations/investor-home/>), press releases, SEC filings, public conference calls and corporate Twitter account (<https://twitter.com/nemusbioscience>) in order to achieve broad, non-exclusionary distribution of information to the public and to comply with our disclosure obligations under Regulation FD. We encourage our investors and others to monitor and review the information we make public in these locations as such information could be deemed to be material information. Please note that this list may be updated from time to time.

ABOUT NEMUS BIOSCIENCE, INC.

The Company is a biopharmaceutical company, headquartered in Long beach, California, focused on the discovery, development, and commercialization of cannabinoid-based therapeutics for significant unmet medical needs in global markets. Utilizing certain proprietary technology licensed from the University of Mississippi, Nemus is working to develop novel ways to deliver cannabinoid-based drugs for specific indications, with the aim of optimizing the clinical effects of such drugs, while limiting potential adverse events. Nemus' strategy is to explore the use of synthetic compounds, alone or in combination with developmental partners. The Company is led by a highly qualified team of executives with decades of biopharmaceutical experience and significant background in early-stage drug development.

For more information, visit <http://www.Nemusbioscience.com>.

CONTACTS:

Nemus Investor Relations:
PCG Advisory Group
Adam Holdsworth
Email: adamh@pcgadvisory.com
Phone: 646-862-4607



Source: Nemus Bioscience, Inc.